Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if TNGX is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
65 top institutions tracked
Last 13F trend: accumulating (light)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 9 days ago
Red flags: 0
249 filers reported a long position in TNGX for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| RTW INVESTMENTS, LP | $434.5M | 13.9M | +4.5% |
| BlackRock, Inc. | $388.8M | 12.4M | +42.2% |
| FMR LLC | $385.5M | 12.3M | +24.5% |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $383.8M | 12.3M | +35% |
| Boxer Capital Management, LLC | $340M | 10.9M | Unchanged |
| GOLDMAN SACHS GROUP INC | $312M | 10M | +96.6% |
| TCG Crossover Management, LLC | $283.9M | 9.1M | -13.8% |
| Paradigm Biocapital Advisors LP | $198.7M | 6.4M | +58.6% |
| PRICE T ROWE ASSOCIATES INC /MD/ | $198.5M | 6.3M | +613.8% |
| Siren, L.L.C. | $193.2M | 6.2M | +9.2% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.